Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies

Nature Reviews Cancer volume 25, pages 561–563 (2025)Cite this article

Subjects

Access through your institution
Buy or subscribe

We read with interest the Review by Peuget et al. (Peuget, S., Zhou, X. & Selivanova, G. Translating p53-based therapies for cancer into the clinic. Nat. Rev. Cancer 24, 192–215 (2024))1 that introduces the development of p53-based therapies. We fully agree with the tremendous clinical value of p53-targeting drugs, as TP53 is the most commonly mutated gene in cancer1. However, we would like to point out that the descriptions of small-molecule compounds that can rescue two or more different types of p53 mutant need to be given with extreme caution. Of the 23 registered p53-rescue trials, 17 trials are investigating these compounds in over 1,000 patients with cancer without differentiating the TP53 mutations (Supplementary Table 1).

Small-molecule compounds that bind mutant p53 and restore its tumour-suppressive function have been extensively pursued over the past decades, with at least 71 rescue compounds identified2,3,4. The majority of these are termed generic rescue compounds and can rescue numerous mutants simultaneously, spawning hundreds of basic and clinical studies using these compounds to rescue arbitrarily selected p53 mutants. However, based on the logic derived from the diverse mechanisms of action of p53 mutants (Fig. 1b) and increasing experimental validations5,6,7, a consensus is forming that no generic rescue compound can provide a ‘one-size-fits-all’ solution to rescue two or more types of p53 mutant. For example, a p53-thermostabilizing compound can shift the ‘unfolding–folding’ dynamic balance towards folding, thereby promoting the refolding of structural mutants and rescuing them. Thus, such a compound is both mechanistically and experimentally validated as ineffective in rescuing p53 truncation mutants that lack large stretches of amino acids, or DNA-contact mutants that lack DNA-binding amino acids5,6,7. Similarly, a DNA-contact mutant-rescue compound (if one were to exist) should act by compensating for the lost DNA-binding amino acids and, thus, mechanistically could not rescue structural mutants, which are unfolded.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The diverse mechanisms underlying inactivation and reactivation of p53 mutants.

References

  1. Peuget, S., Zhou, X. & Selivanova, G. Translating p53-based therapies for cancer into the clinic. Nat. Rev. Cancer 24, 192–215 (2024).

    Article  CAS  PubMed  Google Scholar 

  2. Wang, H., Guo, M., Wei, H. & Chen, Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct. Target. Ther. 8, 92 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sabapathy, K. & Lane, D. P. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat. Rev. Clin. Oncol. 15, 13–30 (2018).

    Article  CAS  PubMed  Google Scholar 

  4. Gomes, A. S., Ramos, H., Inga, A., Sousa, E. & Saraiva, L. Structural and drug targeting insights on mutant p53. Cancers 13, 3344 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Xiao, S. et al. Characterization of the generic mutant p53-rescue compounds in a broad range of assays. Cancer Cell 42, 325–327 (2024). The only study that compares side by side the rescue effectiveness of all available mutant p53-rescue compounds.

    Article  CAS  PubMed  Google Scholar 

  6. Song, H. et al. Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Sci. Transl. Med. 15, eabn9155 (2023). The first study that experimentally determines the rescue potencies of a rescue compound to hundreds of p53 mutants.

    Article  CAS  PubMed  Google Scholar 

  7. Chen, S. et al. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site. Cancer Cell 39, 225–239.e228 (2021). The first study to demonstrate a structural mechanism underlying how a small molecule can generically rescue various p53 mutants.

    Article  PubMed  Google Scholar 

  8. Bykov, V. J. N. et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282–288 (2002).

    Article  CAS  PubMed  Google Scholar 

  9. Joerger, A. C. & Fersht, A. R. The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu. Rev. Biochem. 85, 375–404 (2016).

    Article  CAS  PubMed  Google Scholar 

  10. Degtjarik, O. et al. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Nat. Commun. 12, 7057 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors are funded by National Natural Science Foundation of China (82425001 and 82130075) and Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0501300 and 2024ZD0519600).

Author information

Author notes

  1. These authors contributed equally: Jiaqi Wu, Huaxin Song, Shujun Xiao.

Authors and Affiliations

  1. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine (Shanghai), Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Jiaqi Wu, Huaxin Song, Shujun Xiao & Min Lu

Authors
  1. Jiaqi Wu
    View author publications

    Search author on:PubMed Google Scholar

  2. Huaxin Song
    View author publications

    Search author on:PubMed Google Scholar

  3. Shujun Xiao
    View author publications

    Search author on:PubMed Google Scholar

  4. Min Lu
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Min Lu.

Ethics declarations

Competing interests

M.L. and H.S. are co-authors of the patents ‘PANDA as a novel therapeutic’ (PCT/CN2018/085190) and ‘mp53 rescue compounds and methods of treating a p53 disorder’ (PCT/CN2019/070117). J.W. and S.X. declare no competing interests.

Additional information

Related links

PANDA (p53 and arsenic) project: www.rescuep53.net

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, J., Song, H., Xiao, S. et al. Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies. Nat Rev Cancer 25, 561–563 (2025). https://doi.org/10.1038/s41568-025-00826-7

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41568-025-00826-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer